Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials.

Maryam Teimouri, Masoud Homayouni-Tabrizi, Arezoo Rajabian, Hamed Amiri, Hossein Hosseini

Journal: Complementary therapies in medicine 2022;70():102863

PMID: 35905799

Free Full Text on Elsevier Science View on PubMed

Plain Language Summary

Cardiovascular diseases (CVDs) include various heart or/and blood vessel disorders, such as cerebrovascular disease, congenital heart disease, and coronary artery disease. It is well shown that prolonged or chronic inflammation plays a key role in the pathogenesis of several disorders, especially CVDs. Resveratrol has recently been considered a choice for preventing and treating inflammatory conditions. The aim of this study was to evaluate the impact of resveratrol on serum/plasma concentration of specific inflammatory markers - tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and c-reactive protein (CRP) - in patients with CVDs. This study is a systematic review and meta-analysis of six randomised controlled studies with a total of 415 participants. Results show that resveratrol significantly decreases CRP and TNF-α concentration; however, it did not significantly affect the serum concentration of IL-6 in patients with CVDs. Authors conclude that there is a potential preventive effect of resveratrol supplementation on inflammatory conditions in CVD patients. However, larger randomised clinical trials are needed to further investigate and explore the effects of resveratrol supplementations.

Abstract

BACKGROUND

Chronic inflammation is one of the most important factors involved in the development and progression of cardiovascular disease (CVDs). Accumulating evidence has described the effect of resveratrol, a natural polyphenolic compound, on biomarkers of inflammation among patients with CVDs; however, findings are controversial. Here we performed a systematic review and meta-analysis of randomized controlled trials to evaluate the effect of resveratrol supplements on TNF-α, IL-6, and CRP levels in CVDs patients.

METHODS

Online research was conducted in the following database: MEDLINE, EMBASE, Cochrane Library, Web of Science databases, and Scopus. This systematic review and meta-analysis were conducted to investigate the effects of resveratrol supplements on inflammatory biomarkers among patients with CVDs. The meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V3 software.

RESULTS

Six RCTs met the inclusion criteria and were selected for the current meta-analysis. Our results demonstrated that resveratrol significantly decreases serum levels of CRP (MD = -0.63, 95 % CI: -0.1.13, -0.12; p = 0.01), and TNF-α (MD = -0.55, 95 % CI: -1.04, -0.06; p = 0.02), however, resveratrol had not significant effect on serum concentration of IL-6 (MD = -0.12, 95 % CI: -0.52, 0.27; p = 0.53), in patients with CVDs.

CONCLUSION

Our results suggest that resveratrol can be used as a potential treatment in patients with CVD by reducing inflammatory conditions.

Address: Department of Clinical Biochemistry, School of Allied Medical Sciences, Shahroud University of Medical Sciences, Shahroud, Iran.; Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran.; Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: [email protected].

DOI: 10.1016/j.ctim.2022.102863